This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As these implementations take hold, the emphasis will be on demonstrating measurable return on investment (ROI), with AI driving down administrative burdens, accelerating drugdevelopment, and significantly improving operational efficiency. What’s most exciting to me is AI’s potential impact on personalized medicine.
Mental Health and Well-being: Discussing the importance of mental health, strategies for integration with primarycare, and the use of digital therapeutics. Other Potential Topics: Pharmaceutical Industry: Trends in drugdevelopment, pricing, and access.
A key factor driving the adoption of a digital-first care model is the ability to manage patients regardless of location, thereby decreasing the use of unnecessary resources. Traditional care delivery is not working for far too many consumers. Decentralized clinical trials are already growing in popularity.
It is key for pharmaceutical companies to recognize that efficiency does not override compliance, patient safety or regulatory standards. Jane Reed, Director of Life Sciences at Linguamatics, an IQVIA company Pharmaceuticaldevelopers have always prioritized drug safety. Dave Latshaw, CEO at BioPhy 1.
Drugdevelopment The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates. There are three main advantages to the use of AI in drugdevelopment: width of research, speed of execution, low costs.
To unlock the full potential of care teams, we must have access to actionable, real-time data. Patients are still coming to their doctor’s appointments frustrated that their provider does not have their records from a recent urgent care visit, previous primarycare provider, or a specialist.
They have the potential to become a game changer in healthcare for patients, healthcare professionals, pharmaceuticals and insurance companies. The Digital Therapeutics Alliance developed a definition to differentiate DTx solutions from health and wellness apps. Digital Therapeutics (DTx) have been under the spotlight this past year.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content